EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Remo Panaccione  ¹     Brian G. Feagan  ²     Isabel Redondo  ³     Trevor Lissoos  ⁴     Christian Selinger  ⁵     Vipin Arora  ⁵     Milan Lukas  ⁶     Katsuyoshi Matsuoka  ⁷     Toshifumi Hibi  ^8    
1 University of Calgary, Inflammatory Bowel Disease Center, Calgary, Canada
² Robarts Clinical Trials Inc, London, Canada
³ Eli Lilly Portugal, Produtos Farmacêuticos, Lda., Lisbon, Portugal
⁴ Eli Lilly and Company, Indianapolis, Indiana, United States
⁵ Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
⁶ IBD Clinical and Research Centre, ISCARE Clinical Centre, Prague, Czech Republic
⁷ Toho University Sakura Medical Center, Sakura, Japan
⁸ Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)